Cases of Note

Recent decisions and settlements include:

  • Defeated a motion to dismiss a Complaint filed in the U. S. District of Massachesetts against Sinovac Biotech Ltd. (Nasdaq; SVA) and its Board of Directors for, among other things, breach of fiduciary duties. Sinovac is one of the world's largest manufacturers of vaccines for the COVID19 virus. The Complaint, brought on behalf of Heng Ren Investments alleges that certain members of Sinovac's management intentionally diluted the shares of minority shareholders to facilitate their effort to take the Company private. See “Chinese vaccine firm can't avoid suit alleging wrongful equity dilution,”
  • Settled a defamation claim against online publisher on behalf of individual client for monetary and other relief, including published correction.
  • Obtained dismissal of breach of contract / 93A suit brought against developer in Superior Court
  • Settled a claim on behalf of a consumer debtor against a lender as a result of alleged violations of regulations prohibiting creditors from initiating a communication with a debtor in excess of two such communications in each seven-day period.
  • Resolved 93A claim on behalf of client arising from storage facility’s alleged improper sale of property

Prior to founding RLA in 2020, Attorney Ryan practiced at a respected national law firm where he litigated multiple cases dealing with cutting edge issues in defamation/First Amendment law, securities law and the federal False Claims Act, representing whistleblowers:

  • Argued and successfully obtained dismissal for financial market commentator in defamation case based on investigative report published online. See Decision and Order, Yangtze River Port and Logistics Ltd. v. Hindenburg Research, et. al, No. 150721/2019 (N.Y. Sup. Ct. Feb. 25, 2020) (Sherwood, J.);
  • Secured full dismissal in defamation case brought by publicly traded international corporation against market researcher who published critical market commentary concerning public company. See Decision and Order, Eros Intern. PLC v Mangrove Partners, et al, No. 653096/2017, 2019 WL 1129196 (N.Y. Sup. Ct. Mar. 08, 2019) (Cohen, J.) (affirmed on appeal);
  • Argued and defeated motion to dismiss unsealed False Claims Act case against multiple former pharmaceutical executives for alleged off-label marketing scheme. See United States v. Aegerion Pharm., Inc., No. 13-CV-11785-IT, 2019 WL 1437914 (D. Mass. Mar. 31, 2019); See Reuters’ coverage of the oral argument on the motion to dismiss, quoting Stephen Ryan: Nate Raymond, Ex-Aegerion execs, employees seek to escape drug marketing case, Reuters (Mar. 21, 2019),
  • Worked with numerous SEC whistleblowers in matters resulting in both civil and criminal cases against offending entities and individuals.

Attorney Ryan also has broad experience with complex commercial cases involving G.L. c. 93A, fraud, conversion, breach of contract, non-competes and wrongful termination. He has argued motions to dismiss, summary judgment, attachment hearings, and others. Additional representative matters handled personally by Attorney Ryan include:

  • Bench trial in Suffolk Superior Court concerning damages on commercial loan agreement involving contested signature; result affirmed on appeal
  • Multi-witness evidentiary hearing in Essex Superior Court concerning whether to issue preliminary injunction against tenant after premises purchased by new landlord
  • Bench trial (before clerk magistrate) in Woburn District Court concerning contractor’s suit for damages against condominium association